Liver Drug Metabolism

Oral Bioavailability: Basic Principles, Advanced Concepts, and Applications

Volumn , Issue , 2011, Pages 127-144

  Tompkins, Leslie M ^a   Wang, Hongbing ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Adverse drug reactions (ADRs), genetic polymorphisms concerns of pharmaceutics; Liver drug metabolism, mechanisms pharmaceutical drug metabolism, hurdles to drug bioavailability; Phase II drug metabolism phase I and phase II, linear progression of metabolism for compounds

Indexed keywords

EID: 84870193087     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781118067598.ch10     Document Type: Chapter

References (57)

1. Anundi I, Lahteenmaki T, Rundgren M, Moldeus P, and Lindros KO (1993) Zonation of acetaminophen metabolism and cytochrome P450 2E1-mediated toxicity studied in isolated periportal and perivenous hepatocytes. Biochem Pharmacol 45:1251-1259.
2. Baes M, Gulick T, Choi HS, Martinoli MG, Simha D, and Moore DD (1994) A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements. Mol Cell Biol 14:1544-1552.
3. Bailey DG, Malcolm J, Arnold O, and Spence JD (1998) Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110.
4. Bertilsson G, Heidrich J, Svensson K, Asman M, Jendeberg L, Sydow-Backman M, Ohlsson R, Postlind H, Blomquist P, and Berkenstam A (1998) Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci USA 95:12208-12213.
5. Blumberg B, Sabbagh W Jr, Juguilon H, Bolado J Jr, van Meter CM, Ong ES, and Evans RM (1998) SXR, a novel steroid and xenobiotic-sensing nuclear receptor. Genes Dev 12:3195-3205.
6. Burt CW, McCaig, LF, and Rechtsteiner, EA (2007) Ambulatory medical care utilization estimates for 2005. Advance data from vital and health statistics, in: Advance Data from Vital and Health Statistics (Statistics NCfH, ed.), National Center for Health Statistics, Hyattsville, MD.
7. Coleman MD (2005) Human Drug Metabolism. John Wiley & Sons, Chichester.
8. Dang DT, Chen F, Kohli M, Rago C, Cummins JM, and Dang LH (2005) Glutathione S-transferase {pi}1 promotes tumorigenicity in HCT116 human colon cancer cells. Cancer Res 65:9485-9494.
9. Denison MS, Fisher JM, and Whitlock JP Jr. (1988) The DNA recognition site for the dioxin-Ah receptor complex. Nucleotide sequence and functional analysis. J Biol Chem 263:17221-17224.
10. Faucette SR, Zhang TC, Moore R, Sueyoshi T, Omiecinski CJ, LeCluyse EL, Negishi M, and Wang H (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharmacol Exp Ther 320:72-80.
11. Fisher MB, Paine MF, Strelevitz TJ, and Wrighton SA (2001) The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab Rev 33:273-297.
12. Gamage N, Barnett A, Hempel N, Duggleby RG, Windmill KF, Martin JL, and McManus ME (2006) Human sulfotransferases and their role in chemical metabolism. Toxicol Sci 90:5-22.
13. Groff JL, Gropper, Sareen S, Hunt, and Sara M (1995) Advanced Nutrition and Human Metabolism. West Publishing, New York.
14. Guengerich FP (1999) Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 39:1-17.
15. Guengerich FP (2001) Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol 14:611-650.
16. Haas DW, Ribaudo HJ, Kim RB, Tierney C, Wilkinson GR, Gulick RM, Clifford DB, Hulgan T, Marzolini C, and Acosta EP (2004) Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. Aids 18:2391-2400.
17. Hayes JD, Flanagan JU, and Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51-88.
18. Hoffman EC, Reyes H, Chu FF, Sander F, Conley LH, Brooks BA, and Hankinson O (1991) Cloning of a factor required for activity of the Ah (dioxin) receptor. Science 252:954-958.
19. Honkakoski P, Zelko I, Sueyoshi T, and Negishi M (1998) The nuclear orphan receptor CAR-retinoid X receptor heterodimer activates the phenobarbital-responsive enhancer module of the CYP2B gene. Mol Cell Biol 18:5652-5658.
20. Ingelman-Sundberg M (2004) Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369:89-104.
21. Ingelman-Sundberg M (2005) Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 5:6-13.
22. Izzo AA and Ernst E (2001) Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 61:2163-2175.
23. Kessova I and Cederbaum AI (2003) CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 3:509-518.
24. Kimura S, Umeno M, Skoda RC, Meyer UA, and Gonzalez FJ (1989) The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45:889-904.
25. Kivisto KT, Neuvonen PJ, and Klotz U (1994) Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences. Clin Pharmacokinet 27:1-5.
26. Klaassen CD (2001) Casarett and Doull's Toxicology: The Basic Science of Poisons. McGraw-Hill, New York.
27. Kliewer SA, Goodwin B, and Willson TM (2002) The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev 23:687-702.
28. Lazarou J, Pomeranz BH, and Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 279:1200-1205.
29. Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, and Kliewer SA (1998) The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 102:1016-1023.
30. Li AP, Kaminski DL, and Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104:1-8.
31. Lin HL, Kent UM, and Hollenberg PF (2002) Mechanismbased inactivation of cytochrome P450 3A4 by 17 alphaethynylestradiol: evidence for heme destruction and covalent binding to protein. J Pharmacol Exp Ther 301:160-167.
32. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlage LA, Brown MB, Guo W, and Watkins PB (1997) Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553.
33. Mackenzie P (2006) UDP glucuronosyltransferase homepage, http://som.flinders.edu.au/FUSA/ClinPharm/UGT/.
34. McIlwain CC, Townsend DM, and Tew KD (2006) Glutathione S-transferase polymorphisms: cancer incidence and therapy. Oncogene 25:1639-1648.
35. Nakajima M, Komagata S, Fujiki Y, Kanada Y, Ebi H, Itoh K, Mukai H, Yokoi T, and Minami H (2007) Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/ pharmacodynamics of cyclophosphamide in Japanese cancer patients. Pharmacogenet Genomics 17:431-445.
36. Nebert DW, Nelson DR, Adesnik M, Coon MJ, Estabrook RW, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Kemper B, et al. (1989) The P450 superfamily: updated listing of all genes and recommended nomenclature for the chromosomal loci. DNA 8:1-13.
37. Nebert DW and Russell DW (2002) Clinical importance of the cytochromes P450. Lancet 360:1155-1162.
38. Negishi M, Pedersen LG, Petrotchenko E, Shevtsov S, Gorokhov A, Kakuta Y, and Pedersen LC (2001) Structure and function of sulfotransferases. Arch Biochem Biophys 390:149-157.
39. Nelson D (1999) Cytochrome P450 homepage, http://www.imdb.com/name/nm0765597/.
40. Nelson DR, Kamataki T, Waxman DJ, Guengerich FP, Estabrook RW, Feyereisen R, Gonzalez FJ, Coon MJ, Gunsalus IC, Gotoh O, et al. (1993) The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. DNA Cell Biol 12:1-51.
41. Nelson SD and Gordon WP (1983) Mammalian drug metabolism. J Nat Prod 46:71-78.
42. Ohyama K, Nakajima M, Suzuki M, Shimada N, Yamazaki H, and Yokoi T (2000) Inhibitory effects of amiodarone and its Ndeethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. Br J Clin Pharmacol 49:244-253.
43. Parkinson A (2001) Biotransformation of xenobiotics, in: Casarett and Doull's Toxicology: The Basic Science of Poisons (Klaassen CD, ed.), McGraw-Hill, New York.
44. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, and Falloon J (2000) Indinavir concentrations and St John's wort. Lancet 355:547-548.
45. Poland A, Glover E, and Kende AS (1976) Stereospecific, high affinity binding of 2,3,7,8-tetrachlorodibenzo-p-dioxin by hepatic cytosol. Evidence that the binding species is receptor for induction of aryl hydrocarbon hydroxylase. J Biol Chem 251:4936-4946.
46. Quattrochi LC and Tukey RH (1989) The human cytochrome Cyp1A2 gene contains regulatory elements responsive to 3- methylcholanthrene. Mol Pharmacol 36:66-71.
47. Ritter JK, Yeatman MT, Ferreira P, and Owens I S (1992) Identification of a genetic alteration in the code for bilirubin UDP-glucuronosyltransferase in the UGT1 gen complex of a Crigler-Najjar type patient. J Clin Invest 90:150-155.
48. Ruschitzka F, Meier PJ, Turina M, Luscher TF, and Noll G (2000) Acute heart transplant rejection due to Saint John's wort. Lancet 355:548-549.
49. Satoh T, Hosokawa M, Atsumi R, Suzuki W, Hakusui H, and Nagai E (1994) Metabolic activation of CPT-11, 7-ethyl- 10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin, a novel antitumor agent, by carboxylesterase. Biol Pharm Bull 17:662-664.
50. Schmitt C, Hofmann C, Riek M, Patel A, and Zwanziger E (2009) Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe. Pharmacotherapy 29:1175-1181.
51. Tukey RH and Strassburg CP (2000) Human UDPglucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616.
52. Wang H and LeCluyse EL (2003) Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 42:1331-1357.
53. Wang H and Tompkins LM (2008) CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598-610.
54. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA, and Redinbo MR (2001) The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292:2329-2333.
55. Williams PA, Cosme J, Vinkovic DM, Ward A, Angove HC, Day PJ, Vonrhein C, Tickle IJ, and Jhoti H (2004) Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 305:683-686.
56. Xie HJ, Yasar U, Lundgren S, Griskevicius L, Terelius Y, Hassan M, and Rane A (2003) Role of polymorphic human CYP2B6 in cyclophosphamide bioactivation. Pharmacogenomics J 3:53.
57. Xu RX, Lambert MH, Wisely BB, Warren EN, Weinert EE, Waitt GM, Williams JD, Collins JL, Moore LB, Willson TM, and Moore JT (2004) A structural basis for constitutive activity in the human CAR/RXR[alpha] heterodimer. Molecular Cell 16:919.